Virpax Pharmaceuticals Inc. (VRPX)

Overview

Virpax Pharmaceuticals, Inc. is a pivotal entity in the pharmaceutical landscape, focusing its research and development efforts on creating drug-delivery systems and drug-releasing technologies that aim to revolutionize pain management and treatments for central nervous system disorders. Positioned in the preclinical-stage, this pharmaceutical company is deeply invested in advancing non-opioid and non-addictive solutions for managing pain, alongside developing innovative treatments for central nervous system ailments. Founded in the year 2016 and with its headquarters nestled in Berwyn, Pennsylvania, Virpax Pharmaceuticals distinguishes itself by dedicating its resources to foster ground-breaking therapeutic options that can potentially alter the course of treatment in its targeted domains.

Products and Services

• Epoladerm:

  Epoladerm represents a significant advancement in the treatment of chronic osteoarthritis of the knee, serving as a topical nonsteroidal anti-inflammatory drug. This product candidate showcases Virpax Pharmaceuticals' commitment to offering alternative pain management solutions that steer clear of opioids, aiming to improve the quality of life for individuals suffering from chronic joint pain.

• Probudur:

  A demonstration of Virpax Pharmaceuticals' innovation in postoperative care, Probudur is an injectable local anesthetic presented in a liposomal gel technology. This product candidate is designed to manage postoperative pain, offering a potential non-opioid solution to effectively control pain following surgical procedures.

• Envelta:

  Envelta stands out as a nanotechnology-based intranasal spray drug product candidate that facilitates the delivery of metabolically labile peptide drugs into the brain. This cutting-edge approach aims to address and treat central nervous system disorders by enhancing drug delivery mechanisms to the brain, potentially revolutionizing treatments within this specialized medicinal area.

• PES200:

  Similar to Envelta, PES200 is focused on enabling the delivery of metabolically labile peptide drugs into the brain. Though in a preclinical stage like its peers, it underscores Virpax Pharmaceuticals' dedication to leveraging advanced delivery systems to target the central nervous system, aiming to unveil new therapeutic possibilities.

• AnQlar:

  Amid a world increasingly concerned with viral infections, AnQlar emerges as an anti-viral barrier aimed at preventing or reducing the risk or intensity of viral infections in humans, including those caused by influenza and SARS-CoV-2. This innovation reflects Virpax Pharmaceuticals' foresight and adaptability in responding to global health emergencies with preventive solutions.

• VRP324:

  VRP324 introduces an investigational formulation designed to be delivered via the nasal route, enhancing cannabidiol transport to the brain. This product candidate embodies the company's ongoing efforts in exploring non-traditional pathways and compounds, such as cannabidiol, for potential therapeutic uses in central nervous system disorders.